2015 Pipeline Programs
Target Validation: An Edmond J. Safra Core Program
PRE-PROPOSAL INSTRUCTIONS & REQUIREMENTS
Please review the instructions below before you log in to the online submission system. Please note that applications will only be accepted through the online submission system.
The Target Validation Program will be reviewed in two stages:
- Pre-Proposal Stage:Applicants complete a brief target profile describing the rationale and preliminary data supporting the proposed target’s relevance to Parkinson’s disease.
- Full Proposal Stage:Invited applicants will provide more target details and a specific validation plan demonstrating how manipulating the target may impact PD relevant biological and behavioral phenotypes in a whole mammalian model. Final funding decisions will be made based on this second stage review.
All proposals are treated with confidentiality and will be reviewed by MJFF scientific staff in collaboration with external scientific peer reviewers.
Note: In order to expedite the pre-proposal review process, written critiques will not be provided to applicants not invited to the full application stage.
Online Application Form
- Please complete the online application form with the following information:
Principal Investigator (PI) Contact Information (Institution, Mailing Address, Email, Phone)
CoPI and/or Collaborator (if any) Contact Information (Label – CoPI, Collaborator, Consultant, etc., Paid, Unpaid, Institution, Mailing Address, Email, Phone)
Project Duration (Two-year maximum)
Project Budget ($250,000 maximum total costs)
- The total annual direct costs cannot exceed $100,000
- Budgets should be reasonable for the work proposed.
- Indirect costs are allowed in addition to direct costs as follows:
- Academic institutions may request up to 25% of direct costs
- For-profit organizations may request up to 10% of direct costs
Project Abstract (300 word limit) – Brief summary of the goals of your project
- Please upload as a separate PDF document a completed ‘Target Profile’. A template detailing the required information for the Target Profile can be found below.
Please Note:
- Please make sure to spell out any symbols (e.g., alpha-synuclein) in your online form.Symbols do not transfer correctly to our online system.
- Please type your login email address correctly otherwise you may not receive important information regarding your submission or be able to access your account.
- Once you begin an online application, you may save and return to it before final submission. When ready, please click ‘submit’ to ensure that your submission is delivered promptly to MJFF.
- A notice of proposal receipt is automatically sent by email upon online submission. If this automatic notification is not received within one hour of submission, please contact MJFF at to check on the status of your proposal. Please also expect an email within one-week of the submission deadline notifying you of the status of your proposal’s administrative review.
2015 Pipeline Programs
Target Validation: An Edmond J. Safra Core Program
Target PROFILE template
Please use the following template to create an executive summary of your target profile. Please limit your profile to no more than 2 pages. To save space you may delete the instructional text in each box.
Principal Investigator:
Institution/Company:
Project Title:
TARGET / State the specific, biological target and the hypothesized mechanism and pathway by which the target regulates PD pathogenesis and symptoms.DISEASE RELEVANCE / Indicate where the target is expressed in human tissue and/or how the target is associated with humanParkinson’s disease pathological, symptomatic, and/or dyskinesia phenotypes.
VALIDATIONHISTORY / Indicate if target manipulations show beneficial impact in human clinical studiesinvestigating target-specific therapy, Parkinson’s disease models, and/or in other neurodegenerative models.Previous validation data is not a requirement for this program, but can provide additional rationale for a particular target.
VALIDATION PLAN AND RESOURCE AVAILABILITY / Describe the methodsand animal models that will be used for target validation. If using pharmacological methods, provideinformation detailing the compound’s ability to reach and engage the target in vivo. If using genetic methods, please indicate the approach (siRNA, viral vector overexpression, knockdown, etc.).Please describe the whole-animal model to be used for validating the target and what PD-relevant features will be measured. Please provide tool compound and animal model availability and status (e.g. breeding programs, virus generation, etc.).
FUTURE OBJECTIVES / Describehow a successful project outcomewill lead to therapeutic development.